nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—hindbrain—amyotrophic lateral sclerosis	0.0206	0.182	CbGeAlD
Trametinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.018	0.0436	CcSEcCtD
Trametinib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0167	0.0403	CcSEcCtD
Trametinib—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.0163	0.0393	CcSEcCtD
Trametinib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.0152	0.0367	CcSEcCtD
Trametinib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.0138	0.0334	CcSEcCtD
Trametinib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0321	CcSEcCtD
Trametinib—MAP2K1—embryo—amyotrophic lateral sclerosis	0.0129	0.114	CbGeAlD
Trametinib—MAP2K1—brainstem—amyotrophic lateral sclerosis	0.0118	0.105	CbGeAlD
Trametinib—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0112	0.0271	CcSEcCtD
Trametinib—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0247	CcSEcCtD
Trametinib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0245	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00924	0.0223	CcSEcCtD
Trametinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00902	0.0218	CcSEcCtD
Trametinib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00835	0.0202	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00771	0.0186	CcSEcCtD
Trametinib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00739	0.0179	CcSEcCtD
Trametinib—MAP2K1—spinal cord—amyotrophic lateral sclerosis	0.00735	0.065	CbGeAlD
Trametinib—MAP2K2—medulla oblongata—amyotrophic lateral sclerosis	0.00725	0.0642	CbGeAlD
Trametinib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00673	0.0163	CcSEcCtD
Trametinib—MAP2K2—spinal cord—amyotrophic lateral sclerosis	0.00647	0.0572	CbGeAlD
Trametinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00623	0.0151	CcSEcCtD
Trametinib—MAP2K1—nervous system—amyotrophic lateral sclerosis	0.00619	0.0548	CbGeAlD
Trametinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.0061	0.0147	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00604	0.0146	CcSEcCtD
Trametinib—MAP2K1—central nervous system—amyotrophic lateral sclerosis	0.00596	0.0527	CbGeAlD
Trametinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00591	0.0143	CcSEcCtD
Trametinib—MAP2K1—cerebellum—amyotrophic lateral sclerosis	0.00583	0.0515	CbGeAlD
Trametinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00568	0.0137	CcSEcCtD
Trametinib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00555	0.0134	CcSEcCtD
Trametinib—MAP2K2—nervous system—amyotrophic lateral sclerosis	0.00545	0.0482	CbGeAlD
Trametinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00542	0.0131	CcSEcCtD
Trametinib—MAP2K2—central nervous system—amyotrophic lateral sclerosis	0.00525	0.0464	CbGeAlD
Trametinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00517	0.0125	CcSEcCtD
Trametinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00517	0.0125	CcSEcCtD
Trametinib—MAP2K2—cerebellum—amyotrophic lateral sclerosis	0.00513	0.0454	CbGeAlD
Trametinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00504	0.0122	CcSEcCtD
Trametinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00502	0.0121	CcSEcCtD
Trametinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00493	0.0119	CcSEcCtD
Trametinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00487	0.0118	CcSEcCtD
Trametinib—MAP2K1—brain—amyotrophic lateral sclerosis	0.00473	0.0419	CbGeAlD
Trametinib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00472	0.0114	CcSEcCtD
Trametinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00466	0.0113	CcSEcCtD
Trametinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00464	0.0112	CcSEcCtD
Trametinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00458	0.0111	CcSEcCtD
Trametinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00457	0.011	CcSEcCtD
Trametinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00456	0.011	CcSEcCtD
Trametinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00455	0.011	CcSEcCtD
Trametinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00433	0.0105	CcSEcCtD
Trametinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0043	0.0104	CcSEcCtD
Trametinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00421	0.0102	CcSEcCtD
Trametinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00418	0.0101	CcSEcCtD
Trametinib—MAP2K2—brain—amyotrophic lateral sclerosis	0.00417	0.0369	CbGeAlD
Trametinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00416	0.0101	CcSEcCtD
Trametinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00414	0.01	CcSEcCtD
Trametinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00982	CcSEcCtD
Trametinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00404	0.00975	CcSEcCtD
Trametinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00955	CcSEcCtD
Trametinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00391	0.00944	CcSEcCtD
Trametinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00938	CcSEcCtD
Trametinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00373	0.00902	CcSEcCtD
Trametinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00361	0.00873	CcSEcCtD
Trametinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00851	CcSEcCtD
Trametinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00842	CcSEcCtD
Trametinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0083	CcSEcCtD
Trametinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00344	0.0083	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00341	0.00825	CcSEcCtD
Trametinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00812	CcSEcCtD
Trametinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00796	CcSEcCtD
Trametinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00327	0.00791	CcSEcCtD
Trametinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00781	CcSEcCtD
Trametinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00779	CcSEcCtD
Trametinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00773	CcSEcCtD
Trametinib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00319	0.0077	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.003	0.00725	CcSEcCtD
Trametinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00298	0.0072	CcSEcCtD
Trametinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00692	CcSEcCtD
Trametinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00687	CcSEcCtD
Trametinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00686	CcSEcCtD
Trametinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00681	CcSEcCtD
Trametinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00651	CcSEcCtD
Trametinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00629	CcSEcCtD
Trametinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00629	CcSEcCtD
Trametinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00571	CcSEcCtD
Trametinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00563	CcSEcCtD
Trametinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00545	CcSEcCtD
Trametinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00526	CcSEcCtD
Trametinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00506	CcSEcCtD
Trametinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00502	CcSEcCtD
Trametinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00501	CcSEcCtD
Trametinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00499	CcSEcCtD
Trametinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00473	CcSEcCtD
Trametinib—CYP2C8—brain—amyotrophic lateral sclerosis	0.00144	0.0128	CbGeAlD
Trametinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.00128	0.0113	CbGeAlD
Trametinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.00123	0.0109	CbGeAlD
Trametinib—MAP2K1—Signaling by ERBB2—CASP9—amyotrophic lateral sclerosis	0.000848	0.00179	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000844	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—CASP9—amyotrophic lateral sclerosis	0.000844	0.00178	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.000843	0.00178	CbGpPWpGaD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000843	0.00178	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000841	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000834	0.00176	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.000833	0.00176	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.000833	0.00176	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.00083	0.00175	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—CASP9—amyotrophic lateral sclerosis	0.000828	0.00175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.00082	0.00173	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.000815	0.00172	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events triggered by IGF1R—IGF1—amyotrophic lateral sclerosis	0.000805	0.0017	CbGpPWpGaD
Trametinib—CYP2C8—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.0008	0.00169	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000796	0.00168	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—CASP9—amyotrophic lateral sclerosis	0.000794	0.00168	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—CASP9—amyotrophic lateral sclerosis	0.000794	0.00168	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—CASP9—amyotrophic lateral sclerosis	0.000794	0.00168	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—BDNF—amyotrophic lateral sclerosis	0.000789	0.00167	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000789	0.00167	CbGpPWpGaD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000788	0.00167	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—CASP9—amyotrophic lateral sclerosis	0.000787	0.00166	CbGpPWpGaD
Trametinib—MAP2K2—Amyotrophic lateral sclerosis (ALS)—TP53—amyotrophic lateral sclerosis	0.000784	0.00166	CbGpPWpGaD
Trametinib—MAP2K2—IGF1R signaling cascade—IGF1—amyotrophic lateral sclerosis	0.000783	0.00166	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.000783	0.00166	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—ERBB4—amyotrophic lateral sclerosis	0.00078	0.00165	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—CASP9—amyotrophic lateral sclerosis	0.00078	0.00165	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000779	0.00165	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—CASP9—amyotrophic lateral sclerosis	0.000776	0.00164	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000776	0.00164	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000772	0.00163	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	0.000767	0.00162	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events triggered by IGF1R—IGF1—amyotrophic lateral sclerosis	0.000753	0.00159	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000751	0.00159	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000747	0.00158	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—BDNF—amyotrophic lateral sclerosis	0.000746	0.00158	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000745	0.00157	CbGpPWpGaD
Trametinib—MAP2K2—SHP2 signaling—VEGFA—amyotrophic lateral sclerosis	0.00074	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—ATF1—amyotrophic lateral sclerosis	0.000738	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—CASP3—amyotrophic lateral sclerosis	0.000736	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—IGF1R signaling cascade—IGF1—amyotrophic lateral sclerosis	0.000733	0.00155	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—ERBB4—amyotrophic lateral sclerosis	0.000733	0.00155	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—ERBB4—amyotrophic lateral sclerosis	0.000729	0.00154	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000726	0.00153	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000726	0.00153	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000726	0.00153	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—ERBB4—amyotrophic lateral sclerosis	0.000726	0.00153	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—ERBB4—amyotrophic lateral sclerosis	0.000722	0.00153	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.00072	0.00152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000713	0.00151	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.00071	0.0015	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—CASP9—amyotrophic lateral sclerosis	0.000703	0.00149	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—BDNF—amyotrophic lateral sclerosis	0.000698	0.00147	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TPK1—amyotrophic lateral sclerosis	0.000696	0.00147	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—MMP9—amyotrophic lateral sclerosis	0.000695	0.00147	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000693	0.00146	CbGpPWpGaD
Trametinib—MAP2K1—SHP2 signaling—VEGFA—amyotrophic lateral sclerosis	0.000693	0.00146	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—ERBB4—amyotrophic lateral sclerosis	0.000679	0.00144	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—ERBB4—amyotrophic lateral sclerosis	0.000679	0.00144	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—ERBB4—amyotrophic lateral sclerosis	0.000679	0.00144	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—VEGFA—amyotrophic lateral sclerosis	0.000676	0.00143	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—ERBB4—amyotrophic lateral sclerosis	0.000673	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—ERBB4—amyotrophic lateral sclerosis	0.000667	0.00141	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—ERBB4—amyotrophic lateral sclerosis	0.000664	0.0014	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IGF1—amyotrophic lateral sclerosis	0.000659	0.00139	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—SQSTM1—amyotrophic lateral sclerosis	0.000658	0.00139	CbGpPWpGaD
Trametinib—MAP2K2—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—amyotrophic lateral sclerosis	0.000652	0.00138	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TPK1—amyotrophic lateral sclerosis	0.000651	0.00138	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000648	0.00137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000647	0.00137	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000643	0.00136	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—VEGFA—amyotrophic lateral sclerosis	0.000632	0.00134	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.00063	0.00133	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000616	0.0013	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—SQSTM1—amyotrophic lateral sclerosis	0.000616	0.0013	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—amyotrophic lateral sclerosis	0.00061	0.00129	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000607	0.00128	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000605	0.00128	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000602	0.00127	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000601	0.00127	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000578	0.00122	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000571	0.00121	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.000568	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Corticotropin-releasing hormone—CASP3—amyotrophic lateral sclerosis	0.000564	0.00119	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000563	0.00119	CbGpPWpGaD
Trametinib—MAP2K2—Disease—VTA1—amyotrophic lateral sclerosis	0.000556	0.00118	CbGpPWpGaD
Trametinib—MAP2K1—ErbB Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000554	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000541	0.00114	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000534	0.00113	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000524	0.00111	CbGpPWpGaD
Trametinib—MAP2K1—Disease—VTA1—amyotrophic lateral sclerosis	0.00052	0.0011	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000511	0.00108	CbGpPWpGaD
Trametinib—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000498	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000495	0.00105	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000492	0.00104	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000478	0.00101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000463	0.000978	CbGpPWpGaD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000453	0.000959	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	0.000439	0.000927	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000429	0.000907	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000428	0.000905	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000424	0.000897	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	0.000424	0.000896	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000421	0.000891	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000421	0.000891	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	0.00041	0.000867	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000409	0.000864	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000405	0.000856	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000401	0.000847	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—TP53—amyotrophic lateral sclerosis	0.000397	0.000838	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000394	0.000833	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000394	0.000833	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PLB1—amyotrophic lateral sclerosis	0.000381	0.000806	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000379	0.000801	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000373	0.000787	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000358	0.000757	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PLB1—amyotrophic lateral sclerosis	0.000357	0.000754	CbGpPWpGaD
Trametinib—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000353	0.000746	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000349	0.000737	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000346	0.000732	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000342	0.000724	CbGpPWpGaD
Trametinib—MAP2K2—Disease—VCP—amyotrophic lateral sclerosis	0.00034	0.000718	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000339	0.000716	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000337	0.000713	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000336	0.000711	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.00033	0.000697	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000325	0.000688	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000324	0.000684	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00032	0.000677	CbGpPWpGaD
Trametinib—MAP2K1—Disease—VCP—amyotrophic lateral sclerosis	0.000318	0.000672	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000315	0.000665	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000315	0.000665	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000308	0.000652	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.00029	0.000612	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	0.000286	0.000606	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000282	0.000596	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000274	0.00058	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000274	0.00058	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000271	0.000573	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	0.000268	0.000567	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000267	0.000564	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000267	0.000564	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000264	0.000558	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000256	0.000541	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000251	0.00053	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000251	0.00053	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00025	0.000528	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CST3—amyotrophic lateral sclerosis	0.000244	0.000515	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000243	0.000514	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000239	0.000505	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000238	0.000503	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000235	0.000496	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000234	0.000496	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000233	0.000493	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00023	0.000487	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CST3—amyotrophic lateral sclerosis	0.000228	0.000482	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000228	0.000481	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000223	0.000472	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000223	0.00047	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000219	0.000464	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000219	0.000463	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000216	0.000456	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000215	0.000454	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000208	0.00044	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000205	0.000432	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000202	0.000428	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000202	0.000426	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ATF1—amyotrophic lateral sclerosis	0.000202	0.000426	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000201	0.000425	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	0.000198	0.000419	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—amyotrophic lateral sclerosis	0.000195	0.000412	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000192	0.000406	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CASP9—amyotrophic lateral sclerosis	0.000192	0.000406	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000191	0.000405	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000189	0.0004	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000189	0.0004	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ATF1—amyotrophic lateral sclerosis	0.000189	0.000399	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000187	0.000395	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CASP9—amyotrophic lateral sclerosis	0.00018	0.00038	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CASP9—amyotrophic lateral sclerosis	0.000177	0.000375	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	0.000175	0.00037	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000169	0.000357	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CASP9—amyotrophic lateral sclerosis	0.000166	0.000351	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000164	0.000347	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000158	0.000334	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000155	0.000327	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000154	0.000325	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB4—amyotrophic lateral sclerosis	0.000152	0.000321	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00015	0.000318	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000149	0.000316	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000149	0.000314	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000147	0.000311	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000147	0.000311	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000145	0.000306	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB4—amyotrophic lateral sclerosis	0.000142	0.0003	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.00014	0.000296	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	0.000139	0.000294	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000139	0.000294	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	0.000139	0.000293	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—C3—amyotrophic lateral sclerosis	0.000137	0.000289	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000135	0.000285	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	0.000133	0.000282	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.00013	0.000276	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.00013	0.000275	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—C3—amyotrophic lateral sclerosis	0.000128	0.00027	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000126	0.000267	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000125	0.000265	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	0.000125	0.000264	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000124	0.000262	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000122	0.000258	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000118	0.000249	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOE—amyotrophic lateral sclerosis	0.000117	0.000248	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000116	0.000245	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000114	0.000241	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOE—amyotrophic lateral sclerosis	0.00011	0.000232	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	0.000106	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000106	0.000225	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.000104	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.99e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.94e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.35e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.83e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.26e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.22e-05	0.000174	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	8.07e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—amyotrophic lateral sclerosis	8.04e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.69e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—amyotrophic lateral sclerosis	7.52e-05	0.000159	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	7.44e-05	0.000157	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.12e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.79e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.35e-05	0.000134	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.12e-05	0.000129	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	6.11e-05	0.000129	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.62e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.23e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.94e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.89e-05	0.000103	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	4.63e-05	9.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.62e-05	9.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.44e-05	9.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.15e-05	8.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.35e-05	7.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.29e-05	6.94e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.17e-05	6.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.14e-05	6.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.02e-05	6.38e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.48e-05	5.25e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.7e-05	3.6e-05	CbGpPWpGaD
